Journal article
The effect of rituximab on vaccine responses in patients with immune thrombocytopenia
Abstract
B-cell depletion may impair vaccine responses and increase infection risk in patients with immune thrombocytopenia (ITP). We investigated the effects of rituximab on antibody and cellular responses to Streptococcus pneumoniae polysaccharide and Haemophilus influenzae type b (Hib) vaccines in ITP patients. Of 60 patients in the main trial, 24 patients received both vaccines 6 months after rituximab (n = 17) or placebo (n = 7). Among 20 evaluable …
Authors
Nazi I; Kelton JG; Larché M; Snider DP; Heddle NM; Crowther MA; Cook RJ; Tinmouth AT; Mangel J; Arnold DM
Journal
Blood, Vol. 122, No. 11, pp. 1946–1953
Publisher
American Society of Hematology
Publication Date
September 12, 2013
DOI
10.1182/blood-2013-04-494096
ISSN
0006-4971
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
AdultAgedAntibodies, BacterialAntibodies, Monoclonal, Murine-DerivedB-Lymphocyte SubsetsBacterial CapsulesCombined Modality TherapyDouble-Blind MethodDrug Therapy, CombinationFemaleHaemophilus VaccinesHaemophilus influenzae type bHumansImmunity, CellularInterferon-gammaMaleMiddle AgedProspective StudiesRituximabT-LymphocytesThrombocytopeniaTreatment Outcome